Revenues of biotech sector surge to $4 billion

June 18, 2011 10:02 pm | Updated 10:24 pm IST - BANGALORE:

The Indian biotech and life sciences industry recorded the fastest pace of growth in the last five years in 2010-11 to touch revenues of $4 billion (Rs.18,399.34 crore), according to a survey.

Of this, the biotech industry contributed Rs.17,249.34 crore, while the life science education market made up the remaining Rs.1,150 crore, according to the 9th annual BioSpectrum-Association of Biotechnology Led Enterprises (ABLE) survey.

The biotech industry, without the life sciences education component, recorded a revenue growth of 21.5 per cent vis-a-vis 2009-10 revenues of Rs.14,199 crore.

The top 10 South-based companies, led by Biocon, accounted for $1 billion (Rs.4,816 crore) in revenues.

The contribution of the BioPharma, BioServices, BioAgri, Bioindustrials and Bioinformatics verticals was Rs.10,645 crore, Rs.3,245.97 crore, Rs.2,480 crore, Rs.626 crore and Rs.252 crore, respectively. The BioPharma vertical contributed almost two-fifths of industry revenues, followed by BioServices with 18.82 per cent and BioAgri with a 14.38 per cent contribution. Bioindustrials and BioInformatics made up the rest of the industry revenue.

Growth of biologics in the domestic market gave an 8 per cent boost to the BioPharma segment which clocked about 21 per cent growth in 2010-11.

Biocon retained its top slot of number one company in the overall revenue ranking, growing at a healthy 26 per cent. Of the top 20 companies, Shantha Biotech and Jubilant Life Sciences faced a drop in revenue while Ankur Seeds posted a spectacular growth in revenues.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.